pyrazines has been researched along with palbociclib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, I; Chen-Kiang, S; Di Liberto, M; Garcia, J; Huang, X; Menu, E; Toogood, PL; Vanderkerken, K | 1 |
| Bouvet, M; Chishima, T; DeLong, JC; Dry, SM; Eckardt, MA; Eilber, FC; Endo, I; Federman, N; Hiroshima, Y; Hoffman, RM; Igarashi, K; James, AW; Kawaguchi, K; Kiyuna, T; Li, Y; Matsuyama, R; Murakami, T; Russell, T; Singh, AS; Tanaka, K; Yanagawa, J; Zhang, Y | 1 |
2 other study(ies) available for pyrazines and palbociclib
| Article | Year |
|---|---|
A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p27; Enzyme Inhibitors; Humans; Mice; Mice, Inbred C57BL; Multiple Myeloma; Neoplasm Transplantation; Piperazines; Pyrazines; Pyridines | 2008 |
Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Topics: Animals; Bone Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p18; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Mice; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Piperazines; Pyrazines; Pyridines; Receptor, IGF Type 1; RNA-Binding Protein FUS; Sarcoma, Ewing; Xenograft Model Antitumor Assays | 2016 |